Search Results - "Belotti, Daniela"
-
1
MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a study protocol for a multicenter, double-blind, randomised, placebo-controlled phase II trial
Published in Intensive care medicine experimental (25-08-2023)“…Background Traumatic brain injury (TBI) is a significant cause of death and disability, with no effective neuroprotective drugs currently available for its…”
Get full text
Journal Article -
2
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies
Published in Thrombosis and haemostasis (01-02-2009)“…Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease characterized by thrombocytopenia, microangiopathic haemolytic anemia, neurological and…”
Get more information
Journal Article -
3
Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133 + cells in ischemic refractory cardiomyopathy trial (RECARDIO)
Published in Stem cell research & therapy (14-09-2018)“…Cell therapy with bone marrow (BM)-derived progenitors has emerged as a promising therapeutic for refractory angina (RA) patients. In the present study, we…”
Get full text
Journal Article -
4
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies
Published in Thrombosis and haemostasis (01-03-2005)“…Endothelial injury is the central factor in the events leading to thrombotic microangiopathy (TMA); however, the mechanisms involved are not fully understood…”
Get more information
Journal Article -
5
Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis
Published in Blood cells, molecules, & diseases (01-12-1997)“…The BCR/ABL fusion protein transforms myeloid stem cells. Both chronic myelogenous leukemias (CML) and a subset of acute lymphoblastic leukemias (ALL) are…”
Get full text
Journal Article -
6
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities
Published in The Journal of clinical investigation (01-11-2020)“…BACKGROUNDChimeric antigen receptor (CAR) T cell immunotherapy has resulted in complete remission (CR) and durable response in highly refractory patients…”
Get full text
Journal Article -
7
Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study
Published in Nature medicine (01-01-2023)“…Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS), combining neuroprotection and immunomodulation, represent an unmet…”
Get full text
Journal Article -
8
A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies
Published in Cytotherapy (Oxford, England) (01-05-2022)“…Advanced therapy medicinal products (ATMPs) are novel drugs based on genes, cells or tissues developed to treat many different diseases. Stability studies of…”
Get full text
Journal Article -
9
-
10
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
Published in Blood (15-11-2022)Get full text
Journal Article -
11
Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Relapsed Post-HSCT
Published in Blood (23-11-2021)“…Introduction Allogeneic Chimeric Antigen Receptor (CAR) T cells engineered with non-viral methods offer a modality to reduce costs and logistical complexity of…”
Get full text
Journal Article -
12
Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity
Published in Blood (05-11-2020)“…Background Significant efforts over the past few years led Chimeric Antigen Receptor (CAR) T cell therapy to success in relapsed and refractory (r/r) B-cell…”
Get full text
Journal Article -
13
Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Published in Blood (13-11-2019)“…▪ Background Immunotherapy using patient-derived CAR T cells has achieved complete remission and durable response in highly refractory populations. However,…”
Get full text
Journal Article -
14
Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications
Published in Blood (29-11-2018)“…Background: Acute lymphoblastic leukemia (ALL) is a malignant disorder with a long-term remission of less than 50% of adult patients and of nearly 80% of…”
Get full text
Journal Article -
15
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy
Published in BioMed research international (01-01-2015)“…According to the European Medicine Agency (EMA) regulatory frameworks, Advanced Therapy Medicinal Products (ATMP) represent a new category of drugs in which…”
Get full text
Journal Article -
16
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients
Published in Biology of blood and marrow transplantation (01-03-2014)“…Abstract This phase I multicenter study was aimed at assessing the feasibility and safety of intravenous administration of third party bone marrow–derived…”
Get full text
Journal Article -
17
-
18
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation
Published in Biology of blood and marrow transplantation (01-12-2017)“…Seventy-four patients who relapsed after allogeneic stem cell transplantation were enrolled in a phase IIA study and treated with the sequential infusion of…”
Get full text
Journal Article -
19
GMP‐based CD133+ cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy
Published in Journal of cellular and molecular medicine (01-06-2010)“…The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the preparation of bone marrow (BM)…”
Get full text
Journal Article -
20
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report
Published in Blood (01-08-2005)“…Thrombotic thrombocytopenic purpura (TT666666) is a rare disorder of small vessels that is associated with deficiency of the von Willebrand factor–cleaving…”
Get full text
Journal Article